ARTICLE | Distillery Therapeutics
A synthetic LRH-1 agonist for ulcerative colitis
April 1, 2022 5:18 AM UTC
DISEASE CATEGORY: Autoimmune disease
INDICATION: Inflammatory bowel disease...
BCIQ Company Profiles
BCIQ Target Profiles
Nuclear receptor subfamily 5 group A member 2 (NR5A2) (LRH-1)